Targeting CBP revers chemoresistance to 5-FU of CDX2/REG4 double-positive gastric cancer

Zhiyuan Fan; Fangyuan Li; Xiao Jiang; Tao Pan; Mingde Zang; Jianfang Li; Beiqin Yu; Qingqing Sang; Wentao Liu; Liping Su; Chen Li; Zhenggang Zhu; Min Yan; Chao Yan; Fei Yuan; Bingya Liu

doi:10.1002/ctm2.70069

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (11) : e70069 DOI: 10.1002/ctm2.70069

LETTER TO THE JOURNAL

Targeting CBP revers chemoresistance to 5-FU of CDX2/REG4 double-positive gastric cancer

Zhiyuan Fan ¹^,²^,³
, Fangyuan Li ¹^,³
, Xiao Jiang ⁴
, Tao Pan ¹^,³
, Mingde Zang ¹^,³^,⁵
, Jianfang Li ¹^,³
, Beiqin Yu ¹^,³
, Qingqing Sang ¹^,³
, Wentao Liu ¹^,³
, Liping Su ¹^,³
, Chen Li ¹^,³
, Zhenggang Zhu ¹^,³
, Min Yan ¹^,³
, Chao Yan ¹^,³^,^†
, Fei Yuan ³^,⁶^,^†
, Bingya Liu ¹^,³^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Zhiyuan Fan,Fangyuan Li,Xiao Jiang,Tao Pan,Mingde Zang,Jianfang Li,Beiqin Yu,Qingqing Sang,Wentao Liu,Liping Su,Chen Li,Zhenggang Zhu,Min Yan,Chao Yan,Fei Yuan,Bingya Liu. Targeting CBP revers chemoresistance to 5-FU of CDX2/REG4 double-positive gastric cancer. Clinical and Translational Medicine, 2024, 14(11): e70069 DOI:10.1002/ctm2.70069

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.